S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The 3-Stock Retirement Blueprint (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Sell every Stock except ONE (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The 3-Stock Retirement Blueprint (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Sell every Stock except ONE (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The 3-Stock Retirement Blueprint (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Sell every Stock except ONE (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The 3-Stock Retirement Blueprint (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Sell every Stock except ONE (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears

Rubius Therapeutics - RUBY Stock Forecast, Price & News

$0.43
-0.03 (-6.47%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.43
$0.47
50-Day Range
$0.43
$1.29
52-Week Range
$0.43
$18.39
Volume
1.05 million shs
Average Volume
10.06 million shs
Market Capitalization
$39.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Rubius Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
1,052.6% Upside
$5.00 Price Target
Short Interest
Bearish
5.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$4,590 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.87) to ($1.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

111th out of 1,095 stocks

Biological Products, Except Diagnostic Industry

13th out of 171 stocks

RUBY stock logo

About Rubius Therapeutics (NASDAQ:RUBY) Stock

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RUBY Stock News Headlines

Flagship-backed Vesalius lays off 43%
Rubius Therapeutics scraps platform, lays off 160
Rubius Therapeutics Announces Strategic Update
Rubius Therapeutics Inc - Stock News
What 6 Analyst Ratings Have To Say About Rubius Therapeutics
See More Headlines
Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RUBY Company Calendar

Last Earnings
11/08/2021
Today
10/02/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RUBY
Fax
N/A
Employees
269
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+1,052.6%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-196,550,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.99 per share

Miscellaneous

Free Float
42,649,000
Market Cap
$39.20 million
Optionable
Not Optionable
Beta
2.54

Key Executives

  • Dr. Pablo J. Cagnoni M.D.Dr. Pablo J. Cagnoni M.D. (Age 59)
    Ph.D., CEO, Pres & Director
    Comp: $971.45k
  • Mr. Jose I. Carmona M.B.A. (Age 50)
    CFO, Principal Accounting Officer & Treasurer
    Comp: $659.2k
  • Ms. Dannielle Appelhans (Age 39)
    Chief Operating Officer
    Comp: $422.98k
  • Dr. Laurence A. Turka M.D. (Age 64)
    Chief Scientific Officer and Head of Research & Translational Medicine
    Comp: $626.55k
  • Ms. Maiken Keson-BrookesMs. Maiken Keson-Brookes (Age 49)
    Chief Legal Officer & Corp. Sec.
    Comp: $607.74k
  • Mr. David R. Epstein B.Sc. (Age 60)
    M.B.A., Exec. Director
    Comp: $495k
  • Mr. Spencer Fisk
    Sr. VP & Chief Technical Operations Officer
  • Mr. Mark J. Hernon (Age 58)
    Chief Information Officer
  • Ms. Marissa Hanify
    Director of Corp. Communications
  • Ms. Jill Murray
    VP & Head of HR













RUBY Stock - Frequently Asked Questions

Should I buy or sell Rubius Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" RUBY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RUBY, but not buy additional shares or sell existing shares.
View RUBY analyst ratings
or view top-rated stocks.

What is Rubius Therapeutics' stock price forecast for 2022?

4 Wall Street research analysts have issued 1-year price targets for Rubius Therapeutics' stock. Their RUBY share price forecasts range from $3.00 to $8.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,052.6% from the stock's current price.
View analysts price targets for RUBY
or view top-rated stocks among Wall Street analysts.

How have RUBY shares performed in 2022?

Rubius Therapeutics' stock was trading at $9.68 at the beginning of the year. Since then, RUBY stock has decreased by 95.5% and is now trading at $0.4338.
View the best growth stocks for 2022 here
.

When is Rubius Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RUBY earnings forecast
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.01. During the same period in the previous year, the firm earned ($0.51) EPS.

What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?

12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rubius Therapeutics own?
When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

How do I buy shares of Rubius Therapeutics?

Shares of RUBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $0.43.

How much money does Rubius Therapeutics make?

Rubius Therapeutics (NASDAQ:RUBY) has a market capitalization of $39.20 million. The company earns $-196,550,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

How many employees does Rubius Therapeutics have?

The company employs 269 workers across the globe.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The official website for the company is www.rubiustx.com. The company can be reached via phone at (617) 679-9600 or via email at ir@rubiustx.com.

This page (NASDAQ:RUBY) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.